trial

Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning

NCTId NCT00937261
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 96 (estimated)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2010-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
96 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2009-07
Primary completion
2010-07
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
RisperidonePaliperidone

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
Janssen, L.P. - Investigator Initiated Studies ProgramCollaborator

Investigators

1
Steven M Silverstein, Ph.D.Principal Investigator

Sites

1 total
Irvine, United States

Facts & assertions

4 sourced
Enrollment
96
Phase
PHASE4
Primary Completion Date
2010-07
Status
UNKNOWN
relationships
The graph out of here
drug
Risperidone
drug
Paliperidone
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Steven M Silverstein, Ph.D.
person